ADC · HER2+ 유방암

20개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved20 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCCurated CoreFDAstaleDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, TDxd)

HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow brea… · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 243Status Approved
ADCCurated CoreFDAstaleGileadSN-38 (topoisomerase I inhi…Approved

sacituzumab govitecan-hziy (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy)

TNBC: regimen-specific first-line and previously treated indications; HR-positive/HER2-negative breast cancer after spe… · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 242Status Approved
ADCCurated CoreFDAstaleRocheDM1 (maytansine derivative)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, Trastuzumab Emtansine)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 186Status Approved
ADCCurated CoreFDAstaleDaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan-dlnk (Datroway, DS-1062, Dato-DXd)

HR-positive/HER2-negative breast cancer after specified prior therapies; EGFR-mutated NSCLC after specified prior thera… · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
ADCLimited DatastaleRocheDM1 via butelase-1 with ABD…Phase 2

trastuzumab (Herceptin, Ado-trastuzumab, Ado-trastuzumab (T) emtansine (T-DM1))

Salivary Gland Cancer; HER2 Gene Mutation · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 85Status Recruiting
ADCLimited DatastaleShanghai Fosun Pharmaceutical I…DM1 via butelase-1 with ABD…Phase 3

Kadcyla, T-DM1 (Control drug: Trastuzumab emtansine, Control drug: Trastuzumab emtansine (Kadcyla, T-DM1))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+3
Trials 84Status Active
ADCLimited DatastaleRochePhase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1, T-DM1 and Pertuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 30Status Recruiting
ADCCurated CorestaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Breast Neoplasms; Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#BioJungboMoa-pick#antibody-drug-conjugate+3
Trials 29Status Recruiting
ADCLimited DatastaleGileadPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Sacituzumab Govitecan / Trastuzumab Deruxtecan)

Triple Negative Breast Neoplasms; Neoplasm Metastasis · Triple Negative Breast Neoplasms

#TripleNegativeBreastNeoplasms#ADC#Phase2#antibody-drug-conjugate#NeoplasmMetastasis+1
Trials 24Status Recruiting
ADCLimited DatastaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SalivaryGlandCarcinoma+2
Trials 23Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Her2OverexpressingHigh-RiskNon-M+1
Trials 17Status Active
ADCLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Datopotamab deruxtecan + Durvalumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 11Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active
ADCLimited DatastaleQuantumLeap Healthcare Collabor…Phase 2

[vic-]trastuzumab duocarmazine (SYD985, SYD985 ([vic-]trastuzumab duocarmazine))

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 7Status Recruiting
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab emtansine [Kadcyla])

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 5Status Active
ADCLimited DatastaleSeagen Inc.Phase 2

ladiratuzumab vedotin (ladiratuzumab vedotin)

Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#SmallCellLungCancer+3
Trials 5Status Active
ADCLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Patritumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+2
Trials 4Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#antibody-drug-conjugate#OvarianNeoplasms+2
Trials 1Status Discontinued
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting